One hundred years of neglect in paediatric schistosomiasis

AMAYA L. BUSTINDUY*, STEPHEN WRIGHT2, ELIZABETH C. JOEKES3, NARCIS B. KABATERINE4, JUTTA REINHARD-RUPP5, CHARLES H. KING6, J. RUSSELL STOTHARD7

1 Department of Clinical Research, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
2 Hospital for Tropical Diseases, Mortimer Market Centre, Mortimer Market, London, WC1E 6JD, UK
3 Department of Radiology, The Royal Liverpool University Hospitals NHS Trust, Liverpool, L78XP, UK
4 Schistosomiasis Control Initiative, Imperial College of London, 1 Norfolk Place, Paddington, London, W2 1PG, UK
5 Global Health R&D Department (route de la Verrerie 6, 1267 Coinsins, Switzerland) being part of the biopharma business of Merck KGaA, Darmstadt, Germany
6 Center for Global Health and Diseases, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, 44106, USA
7 Department of Parasitology, Liverpool School of Tropical Medicine, Liverpool, L3 5QA, UK

* Corresponding Author:
Amaya L. Bustinduy
Department of Clinical Research,
London School of Hygiene & Tropical Medicine
Keppel Street, London, WC1E 7HT, UK.
Email: Amaya.Bustinduy@lshtm.ac.uk

Keywords: Paediatrics, schistosomiasis, Schistosoma, praziquantel, intestinal schistosomiasis, urogenital schistosomiasis, ultrasound

Word count: 3,467

Left running header: A. L. Bustinduy and others
Right running header: Paediatric schistosomiasis

Number of figures: 6
Number of tables: 1
SUMMARY

Early in the history of schistosomiasis research, children under five years of age were known to be infected. Although this problem was recognized over one hundred years ago, insufficient action has been taken to address this issue. Under current policy, such infected children only receive their first antiparasitic treatment (praziquantel-PZQ) upon entry into primary school as current mass drug administration (MDA) programmes typically target school-aged children. For many infected children, they will wait up to 6 years before receiving their first medication and significant schistosomiasis-related morbidity may have already established. This inequity would not be accepted for other diseases. To unveil some of the reasons behind this neglect, it is paramount to understand the intricate historical relationship between schistosomiasis and British Imperial medicine, to underpin its lasting influence on today's public health priorities. This review presents a perspective on the historical neglect of paediatric schistosomiasis, focusing on important gaps that persist from the early days after discovery of this parasite. Looking to end this inequity, we address several issues that need to be overcome to move forward towards the lasting success of schistosomiasis control and elimination efforts.
CHILDREN’S ROLE IN THE HISTORY OF SCHISTOSOMIASIS

As Farley has stated: “Tropical medicine from 1898 to the 1970s was fundamentally imperialistic in its basic assumptions, its methods, its goals and its priorities” (Farley, 1991). He then elaborates on this point by stating that “…the basic goal of tropical medicine was to render the tropical world fit for white habitation and white investment”. This period broadly overlaps the time of the discovery of the Schistosoma parasite and the evolution in the biomedical community’s understanding of the parasite’s biology, transmission, and disease manifestations (Fig. 1). Robert T. Leiper, one of the most prominent parasitologists of his time, detailed the African schistosome life cycle in 1916, enabling him to fulfill his mandate: to prevent the transmission of schistosomiasis among British troops during World War I (Stothard et al., 2016). He did so by promoting activities to prevent contact with cercariae-infested waters. Although prevention proved to be the most effective strategy for military troops, it was largely impracticable for indigenous people whose lives depended on irrigation and farming along the Nile Delta, and so could not be enforced.

In terms of the significance of disease in children, The British Colonial Office recognized the inherent risks of raising children in tropical environments where, in 1893, schistosomiasis (Bilharzia) was known to be a common illness. British children were advised to be sent home “…or they will deteriorate physically and morally, grow up slight, weedy, and delicate, with a general feebleness” (Farley, 1991). This is one of the first (indirect) descriptions of the disabling effects of schistosomiasis in children, albeit European.

There was a slow transition from the golden era of descriptive parasitology (1850’s-1920’s), which had a particular interest in environmental practices for disease control, toward disease-centered research, which enabled the discovery of effective drugs. Nevertheless, human Schistosoma-related disease went without an available treatment for over 50 years (Fig. 1). The species-specific description of schistosomiasis-associated morbidity began early on, and necropsy studies primarily contributed to this knowledge of chronic Schistosoma infection (Bustinduy, 2013) (Fig,
1). As a result, the most overt organ-level morbidities, such as hepatosplenomegaly, peri-portal fibrosis, and subsequent portal hypertension with oesophageal varices, were clearly linked to *S. mansoni* and *S. japonicum*. They thus became the primary focus of population-based disease prevalence studies for intestinal forms of schistosomiasis. Haematuria and renal tract pathology (bladder polyps, hydronephrosis and associations to bladder cancer) were identified as complications of *S. haematobium* infection, and these became the focus of efforts for prevention and control for this species (Bustinduy, 2013; Colley et al., 2014). Unfortunately, it took over 100 years to recognize the more widespread and disabling systemic morbidities of *Schistosoma* infection that affect the youngest age groups (King & Dangerfield-Cha, 2008; Koukounari et al., 2006; Koukounari et al., 2007; Mupfasoni et al., 2009; Parraga et al., 1996).

Michael Gelfand, a clinician stationed in Rhodesia (present day Zimbabwe) in the early 1960's, was particularly influential in describing the morbidity of the disease in children. In a detailed clinical description of intestinal schistosomiasis he reported: “This feature of tiredness stands out more in bilharziasis than in any other tropical infestation. The lethargy of the child is often noticed by teachers, who sees him becoming apathetic, falling behind in games and lacking enthusiasm.” (Gelfand, 1967). At the time, these careful clinical observations lacked metrics to accurately measure this ‘fatigue’. Moreover, there was no strategy to treat these children *en masse* (Farley, 1991). Much later, the association between schistosomiasis and decreased physical fitness was documented in Coastal Kenya among boys with urogenital schistosomiasis. This study, although innovative, made use of the Harvard step-test, an instrument not validated for children (Stephenson et al., 1985b). Subsequent work in the same area has identified the 20-meter shuttle run test as an accurate and easy-to-implement field fitness test with excellent correlations between child poly-parasitic status, anaemia and decreased aerobic capacity in over 2,000 children (Bustinduy et al., 2011).

Infection in very young children was particularly well described in clinical accounts from Rhodesia. Up to half of children as young as 2 years old were documented as having egg-patent infection in endemic villages, but in an era of very expensive injectable drug therapy, treating them was not even considered (Fig. 2). Only overt
morbidity was eligible for treatment and this mostly occurred among older children and adults (Gelfand, 1967).

In textbooks and policy literature, school-age children have been characterized as the main transmitters of Schistosoma infection due to their high egg output (peaking in mid-childhood between 10-15 years old) and increased water contact. Owing to their “careless” water use practices, which include frequent wading, playing, and urinating or defecating in or near the water, the Schistosoma transmission cycle is greatly bolstered (Mott et al., 1985; Webbe, 1982). Because detectable Schistosoma-specific morbidity due to advanced organ fibrosis is mostly seen in early adulthood, children were not considered as seriously affected by their infection status (Gryseels, 1989). In addition, risk for disease was erroneously believed to be related only to high-intensity infections (Gryseels, 1989; Warren et al., 1979) Recent studies across Schistosoma species have discredited this paradigm by demonstrating that light-intensity infections already have tangible negative health effects (Bustinduy et al., 2013; Ezeamama et al., 2005b; King, 2015).

In the first wave of population-based morbidity surveys in the 1960s and 1970s, many children were wrongly classified as ‘uninfected’ due to insensitive diagnostic methods (i.e., eggs were not found in urine or stool), and they were termed ‘asymptomatic’ when overt anatomic morbidity was absent. (Mott, 2004; Mott & Cline, 1980) More refined seroprevalence studies have now demonstrated that almost all children from highly endemic areas are infected by the time they reach puberty (Colley et al., 2014). Sadly, this misclassification of infection status has confounded accurate burden of disease estimates and has delayed recognition of Schistosoma infection as a major cause of disease/disability burden in endemic countries. (King, 2010; King, 2015)

Novel diagnostic assays, the Circulating Cathodic Antigen (CCA) and the Circulating Anodic Antigen (CAA), which are able to detect circulating Schistosoma antigens from as little as one worm pair, are now revealing clinically significant worm burdens in individuals who were previously thought to be ‘uninfected’ based on egg-count testing. (Colley et al., 2013; van Dam et al., 2015)
THE FIRST NUTRITIONAL STUDIES

The first nutritional studies in the 1980s were seminal in the field of paediatric schistosomiasis. Conducted in Coastal Kenya by Stephenson and Latham, they opened the door to rigorous research in this area. Epidemiological correlations were made between parasitic infections, including *S. haematobium*, and delayed growth (Stephenson et al., 1985a). Children showed dramatic improvements in appetite and physical fitness after a single dose of metrifonate, an drug effective against *S. haematobium* that was used in that era. (Latham et al., 1990) Unfortunately, little had changed in the same area of Kenya over the next 25 years, when further studies, applying more accurate morbidity metrics, confirmed that decreased fitness and undernutrition were still highly prevalent among children infected with *S. haematobium*. (Bustinduy et al., 2013; Bustinduy et al., 2011).

Progress in this field has been slow but steady. Nutritional studies of the impact of *S. japonicum* infection led by McGarvey and colleagues at Brown University in collaboration with researchers in the Philippines and China, have highlighted the relationship between *S. japonicum* infection and increased systemic inflammation within the human body, which is associated with a negative impact on growth. (McGarvey et al., 1992; McGarvey et al., 1996). Later studies have shown (partial) reversibility of malnutrition after treatment, particularly among those children who are clinically wasted at baseline. (Coutinho et al., 2006a)

FUNCTIONAL MORBIDITIES AFFECTING GROWTH

Advances in the knowledge of host-parasite immune responses have revealed that schistosomiasis is fundamentally a chronic inflammatory disease that affects the entire body. This has led to much wider recognition of morbidities that are linked to the pro-inflammatory state that precedes fibrosis (Coutinho et al., 2006b; Leenstra et al., 2006; Wamachi et al., 2004). These so-called ‘subtle’ morbidities perhaps should be better termed ‘functional’ morbidities, as they impair normal physiological functioning of an infected child. The impact of infection on growth hormone (GH)/insulin-like growth factor-1 (IGF-1) pathways is anabolic to the skeleton, and other inflammatory cytokines also compromise bone growth (Farquharson & Ahmed, 2013). Linear growth can be severely impaired by any chronic inflammation, including inflammation caused by schistosomiasis, and this, in turn, leads to childhood growth stunting. Associated
anaemia of inflammation caused by infection with all species of *Schistosoma* impairs iron storage release and utilization (Ezeamama *et al*., 2005b; Koukounari *et al*., 2006) and this complication most readily manifests itself as decreased physical fitness (Bustinduy *et al*., 2011; Friedman *et al*., 2005; Stephenson *et al*., 1985b), poor concentration, and diminished school performance (Ezeamama *et al*., 2005a; Jukes *et al*., 2002; Nokes *et al*., 1999). If untreated, these manifestations become irreversible with significant lifetime consequences: decreased work productivity as adults, altered fertility in both men and women (Kjetland *et al*., 2012) and decreased quality of life. (Terer *et al*., 2013) The misfortune behind the failure to recognize such ‘functional’ morbidities is that, because they are confounded by other co-endemic diseases, particularly malaria, they are often not adequately recognized as schistosomiasis-related manifestations.

There is a ‘magic window’ of opportunity to treat children who have suffered a growth arrest. This is the ‘catch up’ growth period, when a child can accelerate growth to achieve normal weight and height after an acute health insult, such as schistosomiasis. (Gurarie *et al*., 2011) This window closes when the growth plates fuse, and therefore early intervention is essential to achieve normal height. (Fig. 3)

<< Please insert Figure 3 here>>

ASSOCIATED DISABILITY IN CHILDREN

Why has the negative impact of paediatric schistosomiasis been undervalued? Part of what makes schistosomiasis a ‘neglected’ disease (i.e., counted among the NTDs) is that its perceived importance to health has been linked to its disability-adjusted life-year (DALY) ranking in the WHO-World Bank Global Burden of Disease (GBD) system. In its first iteration, the GBD program intentionally weighted disease impact by age, giving much greater emphasis to diseases that affect 20-30 year olds, and much less to diseases of children under five (Murray CJ, 1996). While this error has been corrected in more recent GBD versions (Salomon *et al*., 2012; Vos *et al*., 2012) schistosomiasis has always been assigned the health impact associated with ‘minor infections’ and given a negligible 0.004-0.005 disability weight. Thus, although there are more than 250 million persons with active (egg-positive) cases, and likely an equivalent number of people with
'egg-negative' *Schistosoma*-related disease, the calculated worldwide DALY impact of schistosomiasis is perceived as less than one-tenth of that attributed to other, more lethal diseases of childhood. In the eyes of many donors and policymakers, this lowers its priority for control and prevention.

To correctly assess the disease burden of *Schistosoma* infection it is important to recognize the lifetime *cumulative* impact of infection, not just in terms of individual organ pathology and dysfunction, but also on the overall whole-body performance of the growing child and young adult. Schistosomiasis that causes chronic anemia, growth faltering, and poor cognitive performance is quite disabling in a setting where resources are limited, and accommodation for disabilities is inadequate. Disease impact does not end when *Schistosoma* infection ends, and the associated loss of schooling and/or reduced growth cannot be reversed by childhood treatments if rapid reinfection is likely where a child lives, plays, and works. Similarly, these losses cannot be reversed once a person reaches adulthood. Once the child passes school age, most of these functional pathologies become irreversible.

**EARLY YEARS (< 5 YEARS OF AGE)**

The institutional apathy regarding treatment of schistosomiasis in children under six is in stark contrast to the recommendations for treatment of preschool children infected with soil-transmitted helminths, a practice that has been at the forefront of paediatric care and treatment campaigns for many years (World Health Organisation, 2007). Children under five years of age are often daily exposed to infected water very early in life, and although initial infection occurs ‘silently’, it generates inflammation that predisposes to organ fibrosis, which will then endure for decades (Colley *et al.*, 2014)

Fig 4. This lack of recognition dates back to early WHO reports on schistosomiasis, in which disease among very young children was described, but then appears to have been forgotten in subsequent formulation of action plans (Mott, 1982). The justification for this health policy gap was two-fold; firstly, young children were considered a lightly-infected population and therefore thought to be at low-risk for schistosomiasis-associated morbidity; secondly, there was no child-friendly formulation for oral treatment that would decrease the risk of choking. Crushing tablets to treat younger children was not considered practical for national programmes, although this approach
is widely performed for pill treatment of other diseases such as tuberculosis (Pineiro Perez et al., 2016). In essence, the under-fives weren’t seriously considered at risk and they were deemed too difficult and unsafe to treat, so they were excluded. It wasn’t until 2010 that the first expert meeting on the inclusion of preschool children in schistosomiasis control efforts was convened at the World Health Organisation (WHO). (World Health Organization., 2011)

From a modern perspective, stronger evidence is emerging that very young preschool children do indeed harbor egg-patent infection. (Bosompem et al., 2004; Odogwu et al., 2006; Sousa-Figueiredo et al., 2008; Verani et al., 2011) and also present with early fibrosis, including hepatosplenic disease due to S. mansoni and early bladder changes due to S. haematobium (Fig 5). Detection of these early fibrotic changes however, may prove challenging.

A recent study in Gabon, piloting a novel protocol for clinical bedside ‘Focused Assessment with Sonography in Urogenital Schistosomiasis’ (FASUS), showed a 41% prevalence of ultrasound detectable urinary tract morbidity in under-fives in a S. haematobium endemic area (Jonathan Remppis et al, manuscript in preparation). This protocol was derived from the WHO’s Niamey ultrasound protocol, widely used in prevalence studies, but not validated as a clinical tool for morbidity assessment in individual patients presenting with symptoms of S. haematobium infection. With the increasing availability of low-cost ultrasound in endemic areas, this approach could provide a point-of-care morbidity detection tool that could allow better definition of the risk of early childhood pathology. (Belard et al., 2016; Richter et al., 2016)

THE EVOLUTION OF ANTI-SCHISTOSOMAL TREATMENT

The first injectable anti-schistosomal treatment, potassium antimony tartrate, or tartar emetic (TE), which contained trivalent antimony, was introduced in 1918 as a drug initially used to treat visceral leishmaniasis. (Christopherson, 1924) (Figure 1)
Although promising at first, it had very limited efficacy and severe side effects (Jordan, 2000). Other drugs followed, including hycaanthone, and oral niridazole each with severe side effects and difficulties in administration. Table 1 summarizes the different anti-schistosomal treatments through time.

Since 1984, praziquantel (PZQ), the current drug of choice, has displaced older drugs of lesser effectiveness for all types of schistosomiasis. (Doenhoff et al., 2008; King et al., 1988; King & Mahmoud, 1989) Its full mechanism of action remains unclear, but it is thought to act on the calcium ion channels of schistosome’s tegument leading to disruption of the parasite’s surface, and exposing it to lethal damage by the host’s immune system (Doenhoff et al., 2008). Adult dose finding studies in the 1970's and 1980's concluded that a single PZQ dose of 40 mg/kg was effective for treating S. haematobium and S. mansoni (Davis et al., 1979; Davis & Wegner, 1979; King et al., 2002). However, in highly-endemic areas, a more intense, repeated dosing approach is likely needed for optimal effect, particularly for S. mansoni (King et al., 2011).

Since its introduction in the 1980s, praziquantel has been used safely in children. However, their recommended dosages were directly extrapolated from pharmacokinetic studies performed in adults (Kabatereine et al., 2007; Mutapi et al., 2011; Xiao, 2005). Work in Uganda in 2010 revealed sub-optimal PZQ cure rates for S. mansoni among preschool children (Sousa-Figueiredo et al., 2010). To explore the appropriateness of age-adjusted dosing, the first pharmacokinetic/pharmacodynamic PZQ study in children in Uganda was conducted in that same area. Results from this recent study showed a very concerning risk of underdosing of children, particularly the younger ones, if standard 40 mg/kg was given. Higher doses may be needed for treating these and other children infected with S. mansoni. (Bustinduy et al., 2016a)
In response to the recommendations from the WHO expert consultation in 2011, (World Health Organization, 2011) an international, non-profit, public-private partnership, called the Praziquantel Consortium has been formed (www.paediatricpraziquantelconsortium.org). Its primary objective is to develop, register, and provide access to a new and more palatable paediatric (orodispersible) formulation of PZQ that can be used to treat young children, including infants and toddlers under the age of 6 years. More importantly, data on the treatment of very young children has been sparse and insufficient to define and confirm the best dosing regimens for young children. These factors mandated the need for the Paediatric PZQ Formulation Program to go through a full clinical drug development pathway. Currently, a Phase 2 study is being conducted in infected preschool children in Ivory Coast. To complement the product development aspects of the program, the consortium has also started to explore means to provide access to the new paediatric treatment as soon as it is marketed. (Bustinduy et al., 2016b)

The success of schistosomiasis control programmes has been very uneven over the last century. Efficacy has varied largely depending on the baseline prevalence of infection. (Jordan, 2000; Wang et al., 2008) Success stories in Japan, Morocco, (Amarir et al., 2011) Iran, and Tunisia give hope to less developed countries that are confronted by the ‘trap’ of self-perpetuating, disease-related poverty (Sacks, 2005). Economically disadvantaged countries are only just now starting to prioritize NTD control (Savioli et al., 2009). To date, implementation of large-scale control efforts in highly endemic areas has not shown permanent success, likely due to ecological factors favoring transmission and human reinfection. Part of the unfortunate lack of success of many control efforts stems from the complex reality of a disease that involves social interactions in hot spots of high transmission. Campaigns frequently miss ‘super-spreaders’- children and individuals highly infected who act as reservoirs (King, 2009). The risk of reinfection or ‘re-worming’ in high-transmission villages in Kenya was found to be as high as 50 % over two years despite ongoing school-based MDA (Satayathum et al., 2006). Even more disheartening was the return to high prevalence in the same areas after control efforts were interrupted for 8 years. (Wang et al., 2012) Older control interventions, based on
better access to clean water and the use of molluscicides, may still have important adjuvant roles to play as part of adaptive strategies in implementing more effective schistosomiasis control programs. (Fenwick et al., 2009; Garba et al., 2009)

The WHO estimates that in the 52 countries in need of schistosomiasis control, over 123 million of school-age children need preventive chemotherapy, out of which only 43 million school age children (34.6 %) may actually receive it. (World Health Organization., 2016) Therefore, there is a large treatment gap remaining among this age group. Because current control strategies primarily target children who attend school, those remaining at home, often with more severe disease, don’t necessarily receive treatment from MDA. A vicious cycle of heavier infection and more severe morbidity ensues (Stothard, 2013; Stothard et al., 2011). This double treatment gap (preschool children and absent school age children) is a health inequality that should be a priority in control program planning and implementation. Ambitious goals set by the WHO 2012 roadmap (Stothard et al., 2014; World Health Organization., 2012) have increased funding and raised the profile of schistosomiasis control, but this leaves a long road ahead for true elimination.

CONCLUSIONS

While there has not been a failure to recognize early childhood Schistosoma-related disease, treatment strategies have not been focused on this phase of infection and its spectrum of disease. It is time for this to change. While MDA continues to lower Schistosoma prevalence, the residual morbidity is significant and persistent low-level worm burdens hinder the plans for elimination in many endemic areas. A more comprehensive integrated management of schistosomiasis, including effective MDA of both preschool and school age children, needs to be adopted as a better strategy for control.

ACKNOWLEDGEMENTS

We would like to thank Jonathan Remppis and Anais Verheyden for contributing their data on preschool children from Gabon. We thank the University for Glasgow for hosting the meeting on celebration of Leiper, Leishman and Robertson. JRS is Director of COUNTDOWN, an implementation research consortium funded by DFID, UK.
REFERENCES


Table 1: Different anti-schistosomal treatments through time.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Active for Species</th>
<th>Route of administration</th>
<th>Main Side effects</th>
<th>Severe Complications</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tartar emetic (TE)</td>
<td><em>S. mansoni</em></td>
<td>Intravenous</td>
<td>• Nausea</td>
<td>• Encephalopathy</td>
<td>(Christopherson, 1918; Davis, 1968; Frank <em>et al.</em>, 2000)</td>
</tr>
<tr>
<td></td>
<td><em>S. haematobium</em></td>
<td></td>
<td>• Vomiting</td>
<td>• Collapse</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>S. japonicum</em></td>
<td></td>
<td>• Muscle/joint pain</td>
<td>• Rash</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• T-wave inversion</td>
<td>• Hepatitis C</td>
<td></td>
</tr>
<tr>
<td>Lucanthone (Miracil®)</td>
<td><em>S. mansoni</em></td>
<td>Oral</td>
<td>• Nausea</td>
<td>• Lethargy</td>
<td>(Blair <em>et al.</em>, 1949; Lees, 1966; Newsome &amp; Halawani, 1950)</td>
</tr>
<tr>
<td></td>
<td><em>S. haematobium</em></td>
<td></td>
<td>• Vomiting</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>S. japonicum</em></td>
<td></td>
<td>• Anxiety</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hycanthione</td>
<td><em>S. mansoni</em></td>
<td>Intramuscular</td>
<td>• Nausea</td>
<td>• Malignancy</td>
<td>(Cook <em>et al.</em>, 1977; Moore, 1972; Warren <em>et al.</em>, 1978)</td>
</tr>
<tr>
<td></td>
<td><em>S. haematobium</em></td>
<td></td>
<td>• Vomiting</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>S. japonicum</em></td>
<td></td>
<td>• Malignancy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Niridazole (Ambilhar®)</td>
<td><em>S. mansoni</em></td>
<td>Oral</td>
<td>• Nausea</td>
<td>• Seizures</td>
<td>(Davis, 1966; Nicholson &amp; McMahon, 1966)</td>
</tr>
<tr>
<td></td>
<td><em>S. haematobium</em></td>
<td></td>
<td>• Vomiting</td>
<td>• Malignancy</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>S. japonicum</em></td>
<td></td>
<td>• Headache</td>
<td>• Death</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Vivid dreams</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Acute confusion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metrifonate</td>
<td><em>S. haematobium</em></td>
<td>Oral</td>
<td>• Nausea</td>
<td>• Bronchospasm</td>
<td>(King <em>et al.</em>, 1988; King <em>et al.</em>, 1990)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Vomiting</td>
<td>• Bradycardia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Headache</td>
<td>• Ataxia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Dizziness</td>
<td>• Respiratory paralysis</td>
<td></td>
</tr>
<tr>
<td>Oxamniquine</td>
<td><em>S. mansoni</em></td>
<td>Oral</td>
<td>• Nausea</td>
<td>• Seizures</td>
<td>(da Silva <em>et al.</em>, 1975; Ferrari <em>et al.</em>, 2003)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Vomiting</td>
<td>• Hallucinations</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Dizziness</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Drowsiness</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Eosinophilia</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

44
| Praziquantel | *S. mansoni*  
| S. haematobium  
| S. japonicum | Oral  
| • Nausea  
| • Vomiting  
| • Abdominal pain  
| • Headache  
| • Dizziness  
| • Drowsiness | Lethargy | (Davis *et al.*, 1979; King *et al.*, 2002) |